Protocol Ledger

NCT06045299 · Phase III · COMPLETED

Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia

Interventional Phase III clinical trial protocol NCT06045299 sponsored by Corxel Pharmaceuticals in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-27 Enrollment: 300 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06045299
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06045299
Protocol FieldVerified Registry Value
NCT IdentifierNCT06045299
Consolidated Lead SponsorCorxel Pharmaceuticals
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment300 participants (ACTUAL)
Registered Start Date2023-09-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI